Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Long-term Debt

Borrowings due after more than one year.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 66.6% from a year ago

Long-term debt stood at $14.99M at the end of Q1 FY2026, down 66.6% from a year earlier and down 34.5% from the prior quarter. Over 3 fiscal years it compounded at -16.6% a year.

Context

  • Long-term debt amounted to 3.0% of total assets at the end of Q1 FY2026, down 22.6 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -66.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.99M-34.5% QoQ
Last fiscal yearDec 2025
$22.88M-56.3% YoY
Year agoMar 2025
$44.93M-66.6% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.6%——
1 year-56.3%——
3-year CAGR-16.6%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
22.88M USD
Year-over-year change
-56.3%
4-year CAGR
+3.5%

Long-term Debt vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's Mar 2026 long-term debt of $14.99M is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -66.6% is the 2nd highest of 3, against a peer median of -47.7%.
  • Long-term debt amounts to 3.0% of total assets for RIGL, versus a peer median of 0.0%.
RIGL Competitors Peer median
Long-term Debt for RIGL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VSTMVerastem, Inc.Mar 2026$76.87M +4.6%+46.0%33.7%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$14.99M -66.6%-16.6%3.0%
CGEMCullinan Therapeutics, Inc.Mar 2026$1.66M ——0.4%
EXELExelixis, Inc.Jul 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.Aug 2026$0 ——0.0%
ANLAdlai Nortye Ltd.Dec 2025$0 ——0.0%
CCCCC4 Therapeutics, Inc.Mar 2026$0 ——0.0%
ALXOALX Oncology Holdings Inc.Mar 2026$0 -100.0%—0.0%
CRDFCardiff Oncology, Inc.Mar 2026$0 ——0.0%
MREOMereo BioPharma Group plcMar 2026$0 ——0.0%
Peer median (excluding RIGL) $0-47.7%+46.0%0.0%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents18.89M24.46M32.79M56.75M40.58M
Short-term Investments106.08M33.75M24.15M20.58M114.38M
Net Receivables15.47M40.32M30.55M41.62M51.76M
Inventory6.62M9.12M5.52M6M11.51M
Other Current Assets08.26M6.26M10.17M21.94M
Total Current Assets154.47M115.9M99.27M135.1M240.17M
Property, Plant & Equipment (Net)11.89M2.79M1.03M338K920K
Goodwill00000
Intangible Assets014.95M13.88M27.1M24.75M
Long-term Investments00000
Tax Assets0000245.85M
Other Non-current Assets974K640K3.06M1.44M1.91M
Total Non-current Assets12.86M18.38M17.96M28.87M273.43M
Total Assets167.33M134.28M117.23M163.98M513.59M
Account Payables3.8M22.51M7.14M3.34M7.19M
Short-term Debt007.23M7.27M30.43M
Tax Payables00000
Deferred Revenue10.51M13.51M17.04M27.8M1.36M
Other Current Liabilities24.2M13.86M12.32M10.14M48.35M
Total Current Liabilities63.55M65.21M53.27M63.3M99.24M
Long-term Debt19.91M39.45M52.37M52.41M22.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities52.73M42.26M39.94M44.98M0
Total Non-current Liabilities73.4M82.68M92.6M97.39M22.88M
Total Liabilities136.95M147.9M145.87M160.69M122.11M
Common Stock172K174K17K18K18K
Retained Earnings(1.32B)(1.38B)(1.41B)(1.39B)(1.02B)
Accumulated OCI(102K)(153K)8K10K181K
Other Stockholders Equity00000
Minority Interest00000
Total Equity30.37M(13.62M)(28.64M)3.29M391.48M
Total Debt30.57M41.55M60.58M59.97M53.3M
Net Debt11.68M17.09M27.79M3.22M12.72M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.